(E)-6-(3,4-Dihydroxystyryl)-4-hydroxy-2H-pyran-2-one

Catalog No. :
ACPRVK628
CAS No. :
555-55-5
Molecular Formula :
C13H10O5
Molecular Weight :
246.22

IUPAC Name:(E)-6-(3,4-dihydroxystyryl)-4-hydroxy-2H-pyran-2-one

(E)-6-(3,4-Dihydroxystyryl)-4-hydroxy-2H-pyran-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$108.00Login to see priceIn stockInquiry
10mg98%$134.00Login to see priceIn stockInquiry
25mg98%$162.00Login to see priceInquiryInquiry
50mg98%$195.00Login to see priceIn stockInquiry
100mg98%$312.00Login to see priceIn stockInquiry
250mg98%$530.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(E)-6-(3,4-Dihydroxystyryl)-4-hydroxy-2H-pyran-2-one
IUPAC Name(E)-6-(3,4-dihydroxystyryl)-4-hydroxy-2H-pyran-2-one
MDL No.MFCD22199534
Molecular FormulaC13H10O5
Molecular Weight246.22
SMILESO=C1C=C(O)C=C(/C=C/C2=CC=C(O)C(O)=C2)O1
InChI KeySGJNQVTUYXCBKH-HNQUOIGGSA-N
Synonym2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-6-hydroxy-pyran-4-one | AM803182 | Hispidin, solid, >=98% (HPLC) | HY-100618 | NCGC00094001-05 | 2-((E)-2-(3,4-DIHYDROXYPHENYL)ETHENYL)-6-HYDROXYPYRAN-4-ONE | (E)-6-(3,4-dihydroxystyryl)-4-hydroxy-2H-pyran-2-one | BRD-
CAS No.555-55-5
PubChem CID54685921

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H317-H319
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACPRVK628 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPRVK628 route product structure diagram
    ACPRVK628555-55-5 In Stock
Inquiry

2. ACPRVK628 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPRVK628 route product structure diagram
    ACPRVK628555-55-5 In Stock
Inquiry

Comments (0)